|1.||Zheng, Yi: 5 articles (03/2006 - 05/2004)|
|2.||Zhao, Peng: 3 articles (10/2013 - 12/2008)|
|3.||Tan, Andrew M: 3 articles (10/2013 - 12/2008)|
|4.||Waxman, Stephen G: 3 articles (10/2013 - 12/2008)|
|5.||Zheng, Jie: 3 articles (01/2006 - 05/2004)|
|6.||Ouyang, Hong Wei: 2 articles (01/2015 - 10/2014)|
|7.||Wu, Yan: 2 articles (01/2015 - 10/2014)|
|8.||Xia, Qingqing: 2 articles (01/2015 - 10/2014)|
|9.||Sun, Heng: 2 articles (01/2015 - 10/2014)|
|10.||Liu, Huanhuan: 2 articles (01/2015 - 10/2014)|
01/01/2014 - "The antiviral potential of NSC23766 was confirmed in mouse experiments, identifying Rac1 as a new cellular target for therapeutic treatment of influenza virus infections. "
11/30/2014 - "Infection of cells by adenoviruses expressing dominant negative Rac1 (Rac1-N17), Cdc42 (Cdc42-N17) or constitutively active RhoA (RhoA-V14), or incubation of cells with pharmacological inhibitors of Rac1 (NSC23766) or Cdc42 (ML141) significantly protected neuroblastoma cells from metformin-induced apoptosis. "
05/18/2004 - "Thus, NSC23766 constitutes a Rac-specific small-molecule inhibitor that could be useful to study the role of Rac in various cellular functions and to reverse tumor cell phenotypes associated with Rac deregulation."
01/01/2013 - "Therefore, a panel of small molecule compounds were derived from NSC23766 and screened for Rac activity inhibition in metastatic cancer cells. "
12/01/2010 - "The new compounds are not toxic to normal mammary epithelial cells and are more efficient (60-70%) than NSC23766 in inhibiting cell migration and reducing cell spreading and extension of lamellipodia, cell functions regulated by Rac that contribute to cancer invasion. "
12/01/2010 - "Several of the NSC23766 derivatives were shown to inhibit Rac1 activity of cancer cells with higher efficiency (20-50% more) than NSC23766. "
01/01/2006 - "NSC23766 also potently inhibited the prostate PC-3 cancer cell proliferation and invasion induced by Rac hyperactivation. "
|5.||Ovarian Neoplasms (Ovarian Cancer)
10/01/2015 - "Studies on immortalized human ovarian adenocarcinoma cells (SKOV3ip) and primary patient-derived ovarian cancer cells show that R-ketorolac is a robust inhibitor of growth factor or serum-dependent Cdc42 and Rac1 activation with a potency and cellular efficacy similar to small-molecule inhibitors of Cdc42 (CID2950007/ML141) and Rac1 (NSC23766). "
|5.||Small Interfering RNA (siRNA)
|6.||GTP Phosphohydrolases (GTPases)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||Messenger RNA (mRNA)
|10.||salicylhydroxamic acid (SHAM)